Revance Therapeutics says entered into services agreement with Ajinomoto Althea

Thursday, Mar 16, 2017

Revance therapeutics inc- on march 14, 2017 co entered into services agreement with ajinomoto althea, inc.- sec filing. Revance therapeutics-under agreement,althea has agreed to provide co with future source of commercial fill/finish services for neuromodulator products.

Revance therapeutics inc- services agreement has an initial term that will expire in seven years.

Revance therapeutics- agreement provides co expanded capacity,second source of drug product manufacturing to support launch of daxibotulinumtoxina for injection (rt002).



Other News